

References

1. Fernando Tadeu Andrade-Rocha, Assessment of Exfoliated Prostate Cells in Semen, *American Journal of Clinical Pathology*, Nov 2007, 128 (5) 788-793; DOI:10.1309/9ELYPH61DBD8AXYC.
2. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. *Hum Pathol* 2004;**35**:122–8.
3. Mukherjee S, Richardson AM, Rodriguez-Canales J, Ylaya K, Erickson HS, et al. (2009) Identification of EpCAM as a molecular target of prostate cancer stroma. *Am J Pathol* 175: 2277–2287. doi: 10.2353/ajpath.2009.090013. pmid:19850885.
4. Drake RR, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A, Nyalwidhe JO, Basu G, Wilkins CE, Gjurich B, Lance RS, Semmes OJ, Medin JA, Kislinger T: In-depth proteomic analyses of direct expressed prostatic secretions. *J Proteome Res*. 2010, 9: 2109-2116.
5. Knuth, S., M. Glidea, R. Tinawi-Aljundi et al. Minimally Invasive OligoFISH Prostate Cancer Screening Test. *Journal of Mol Diagnostics* 2013 Nov;15(6), #ST72
6. Nakai Y, Anai S, Kuwada M, Miyake M, Chihara Y, Tanaka N, Hirayama A, Yoshida K, Hirao Y, Fujimoto K. Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid. *BMC Urol*. 2014 3;14:59. doi: 10.1186/1471-2490-14-59.
7. Furubayashi, N., Negishi, T., Ura, S., Mutaguchi, J., Taguchi, K., Shimokawa, M., & Nakamura, M. (1899). Patients treated with radical prostatectomy with positive digital rectal examination findings in the intermediate-risk group are prone to PSA recurrence. *Oncology Letters*, 0, 0-0. <http://dx.doi.org/10.3892/ol.2016.4485>.
8. Miyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells-monitoring treatment response in prostate cancer. *Nat Rev Clin Oncol* 2014;11: 401–12.
9. Hu B, Rochefort H, Goldkorn A. Circulating tumor cells in prostate cancer. *Cancers* (Basel) 2013;5(4):1676–1690. doi: [10.3390/cancers5041676](https://doi.org/10.3390/cancers5041676)
10. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2008;14:6302-6309. doi: 10.1158/1078-0432.CCR-08-0872.

PAGE 4



Non-Invasive Liquid Biopsy Test Empowers Your Risk Assessment



PAGE 1


Better Diagnostic Information = **Better** Patient Management

The proprietary WaveSense targeted cell isolation and enrichment technology transforms non-invasive liquid biopsies into valuable data sources that enable enhanced diagnostic information.

Use our Prost8 test to non-invasively:

- Differentiate prostate cancer from BPH
- Identify false-negative biopsy results
- Monitor your patients

Powered by the patented, FDA-listed WaveSense nanoparticle technology, Prost8 enables you to non-invasively assess your patient's status throughout the treatment process:



PAGE 2

- | | |
|--------------|--|
| Elevated PSA | ▶ Confirms inflammation |
| | ▶ Confirms malignancy |
| | ▶ Confirms BPH |
| Post-Biopsy | ▶ Identifies false-negative results |
| Surveillance | ▶ Supports non-invasive patient monitoring |

PAGE 3

Easy for you... and your patient!

- Simply collect a urine specimen following a DRE/DRM.
- Send the specimen to us along with the following information and we will report a result within 48 hours:
 - PSA test results
 - DRE result
 - Other pertinent clinical information
- Upon receipt of the specimen, we will use the WaveSense technology to capture, isolate and enrich the prostate cells and, using a range of molecular modalities, our Prost8 test will:
 - Rule in/rule out prostatitis/inflammation
 - Detect malignancy and pre-malignancy
 - Confirm BPH

- Recommended for:
- ▶ Any patient with increase in PSA and/or prostatitis.
 - ▶ Patients not receiving treatment influencing PSA level.
 - ▶ Patients who have not received a prostate massage within 24 hours of sample collection.
 - ▶ Patients who have not ejaculated within 24 hours of sample collection.

- Not Recommended for:
- ▶ Patients receiving any cancer related therapy.
 - ▶ Patients who have received a prostatectomy.